Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

[1]  H. Echizen,et al.  Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes , 1998, Clinical pharmacology and therapeutics.

[2]  A. Sweatt,et al.  A molecular mechanism for genetic warfarin resistance in the rat , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  T. Baglin,et al.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. , 2000, Blood.

[4]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[5]  S. Hutson,et al.  Warfarin Resistance Is Associated with a Protein Component of the Vitamin K 2,3-Epoxide Reductase Enzyme Complex in Rat Liver , 1998, Thrombosis and Haemostasis.

[6]  D. Abernethy,et al.  Selective inhibition of warfarin metabolism by diltiazem in humans. , 1991, The Journal of pharmacology and experimental therapeutics.

[7]  R. Reilly.  Studies on the optical enantiomorphs of warfarin in man , 1974 .

[8]  S. Ishikawa,et al.  Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children , 2000, Clinical pharmacology and therapeutics.

[9]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[10]  S. McGrath,et al.  Cytochrome P450 polymorphisms are associated with reduced warfarin dose. , 2000, Surgery.

[11]  H. Halkin,et al.  Interindividual variability in sensitivity to warfarin‐Nature or nurture? , 2001, Clinical pharmacology and therapeutics.

[12]  S. Higuchi,et al.  Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. , 2000, Therapeutic drug monitoring.

[13]  J. Goldstein,et al.  Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. , 2001, Pharmacogenetics.

[14]  H. Echizen,et al.  Pharmacogenetics of Warfarin Elimination and its Clinical Implications , 2001, Clinical pharmacokinetics.

[15]  J. Goldstein,et al.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.

[16]  J. Hirsh,et al.  Interactions of Warfarin with Drugs and Food , 1994, Annals of Internal Medicine.

[17]  R. O'Reilly.  The second reported kindred with hereditary resistance to oral anticoagulant drugs. , 1970, The New England journal of medicine.

[18]  H Furuya,et al.  Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. , 1995, Pharmacogenetics.

[19]  S. Thompson,et al.  Factors affecting the maintenance dose of warfarin. , 1992, Journal of clinical pathology.

[20]  M. Margaglione,et al.  Genetic Modulation of Oral Anticoagulation with Warfarin , 2000, Thrombosis and Haemostasis.

[21]  R. Kim,et al.  Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.

[22]  Takenoriyamaguchi.  Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation , 2000 .

[23]  H. Chow,et al.  Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. , 2001, Blood.

[24]  U. Seligsohn,et al.  Genetic susceptibility to venous thrombosis. , 2001, The New England journal of medicine.

[25]  T. Meade,et al.  CYP2C9*3 allelic variant and bleeding complications , 1999, The Lancet.

[26]  T. Yamaguchi.  Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. , 2000, Stroke.

[27]  T. Shimizu,et al.  Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. , 1998, Pharmacogenetics.

[28]  J. Goldstein,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.

[29]  H. Echizen,et al.  Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[30]  T. Shimizu,et al.  Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone , 1999, Clinical pharmacology and therapeutics.

[31]  E. Chan,et al.  Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. , 1994, British journal of clinical pharmacology.

[32]  M. Matsumoto,et al.  Anticoagulant therapy in Japanese patients with mechanical mitral valves. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[33]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[34]  M. Kohn,et al.  A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. , 2000, Blood.

[35]  T G Buchman,et al.  Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms , 2001, American journal of hematology.

[36]  R. O'Reilly.  Studies on the optical enantiomorphs of warfarin in man. , 1974, Clinical pharmacology and therapeutics.

[37]  T. Baglin,et al.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. , 2000 .

[38]  F. Kamali,et al.  The influence of age, liver size and enantiomer concentrations on warfarin requirements. , 1995, British journal of clinical pharmacology.

[39]  J. Oldenburg,et al.  Missense mutations at ALA‐10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy , 1997, British journal of haematology.

[40]  R. Tracy,et al.  Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. , 1997, Stroke.

[41]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[42]  S. McGrath,et al.  The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. , 2002, Journal of the American College of Surgeons.

[43]  H. Roh,et al.  Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations , 2002, European Journal of Clinical Pharmacology.

[44]  M H Tarbit,et al.  Genetic analysis of the human cytochrome P450 CYP2C9 locus. , 1996, Pharmacogenetics.

[45]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[46]  G. Aithal,et al.  Warfarin dose requirement and CYP2C9 polymorphisms , 1999, The Lancet.

[47]  H. Halkin,et al.  WARFARIN DOSE REQUIREMENT AND CYP2C9 POLYMORPHISMS. AUTHORS' REPLY , 1999 .

[48]  E. Nanba,et al.  Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. , 2000, Pharmacogenetics.

[49]  E. Spina,et al.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance , 2002, Clinical pharmacology and therapeutics.

[50]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[51]  P. Mannucci,et al.  Genetic control of anticoagulation , 1999, The Lancet.

[52]  H. Kwaan,et al.  Protein C antigen deficiency and warfarin necrosis. , 1986, American journal of clinical pathology.

[53]  H. Echizen,et al.  Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients , 2003, Clinical pharmacology and therapeutics.

[54]  W. Trager,et al.  Genetic association between sensitivity to warfarin and expression of CYP2C9*3. , 1997, Pharmacogenetics.

[55]  J. Hirsh,et al.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 2001, Chest.